Minerva Neurosciences Stock News

LivaNova announced a publication in Contemporary Clinical Trials about the RECOVER study design for VNS Therapy for treatment-resistant depression.

Minerva Neurosciences (NASDAQ:NERV)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report released on Thursday, TipRanks reports. They presently have a $10.0

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Minerva Neurosciences (NERV – Research

Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that it has exercised

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research

Some traders appear to be taking profits off the table after the stock's jump last week.

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Chiasma (CHMA – Research Report) today and set a price

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and succes

Kasar Habasha ta nanata cewa, za ta ci gaba da aikin cike madatsar ruwan kogin Nile, da ake rikici akai na tswon shekaru da makwabtan ta Masar da Sudan dake Gabashin Afirka ko da kuwa ba’a kai ga ci

The drugmaker received good news from the FDA for one of its pipeline candidates.

Minerva Neurosciences Inc (NASDAQ:NERV) has earned a consensus rating of “Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. Three research analysts have

A bolsa paulista buscava firmar o viés positivoo nesta quinta-feira, embora em um ambiente externo ainda volátil, com incertezas relacionadas à pandemia de Covid-19, além da chance de retorno de u

BOVESPA-Índice oscila sem viés claro com exterior ainda volátil por pandemia, comércio